Upgrade to SI Premium - Free Trial

Goldman Sachs Reiterates Buy Rating on Amgen (AMGN) After ESMO Data

September 30, 2019 8:29 AM
Goldman Sachs analyst Terence Flynn reiterated a Buy rating and $243.00 price target on Amgen (NASDAQ: AMGN) after the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments